TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.
Lasho
T L
TL
Tefferi
A
A
Hood
J D
JD
Verstovsek
S
S
Gilliland
D G
DG
Pardanani
A
A
D049109:Cell Proliferation / Q000187:drug effects; D041905:Erythroid Cells / Q000473:pathology*; D006801:Humans; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors / Q000235:genetics; D009154:Mutation; D009196:Myeloproliferative Disorders / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D011759:Pyrrolidines / Q000494:pharmacology*; D053628:Receptors, Thrombopoietin / Q000235:genetics; D013449:Sulfonamides / Q000494:pharmacology*; D014407:Tumor Cells, Cultured; D000096926:Benzenesulfonamides
D053614:Janus Kinase 2; D011759:Pyrrolidines; D053628:Receptors, Thrombopoietin; D013449:Sulfonamides; C082218:MPL protein, human; C528327:fedratinib; D000096926:Benzenesulfonamides; C507924:JAK2 protein, human